hsa-mir-3909: Hsa-mir-3909 is a microRNA that has been studied in relation to various diseases, including rheumatic heart disease (RHD) [PMC9409130]. In patients with RHD, the expression of hsa-mir-3909 is significantly downregulated in the plasma [PMC9409130]. This downregulation of hsa-mir-3909 enhances the IL1 pathway induced by interleukin 1 receptor type 1 (IL1R1), which is the target gene of hsa-mir-3909 [PMC9409130]. Hsa-mir-3909 has also been found to be correlated with rheumatic valvular heart disease [PMC8842963]. It has been shown that hsa-miR-205-3p and hsa-mir-3909 can target the IL-1β-IL-1 receptor pathway, leading to increased inflammation levels [PMC9781220]. Hsa-mir-3909 is located on 22q12.3, and deletions in this region have been associated with neurocristopathy and sensorineural hearing loss [PMC6442922]. In sepsis, hsa-mir-3909 has been identified as a potential regulator of prognosis along with other lncRNAs and miRNAs [PMC9976425]. Hsa-miR-205-3p and hsa-mir-3909 have also been implicated in disease progression, specifically in augmenting the IL1 pathway [PMC8282907]. The expression levels of these miRNAs can be quantified using real-time qPCR techniques [PMC8156444]. The target genes of hsa-miR-205-3p and hsa-mir-3909 include IL-1β and IL1R1 [PMC5857082]. The altered expression of hsa-miR-205-3p and hsa-mir-3909 has been specifically observed in RHD, potentially leading to increased expression of IL-1β and IL1R1 [PMC5857082].